Andrew Adams

Andrew W. Adams (HC), is a Co-Founder and Managing Partner of Oak HC/FT where he focuses on growth equity and early-stage venture opportunities in Healthcare.

Andrew currently serves on the Boards of August Bioservices, DispatchHealth, Everside Health, Galileo, Rialtic, Therapy Brands, Unified Women's Healthcare, US HealthVest and WithMe Health and is a Board Observer at Sema4. Andrew is also actively involved with Independent Living Systems and Precision Medicine Group.

Recent prior investments include Core Informatics (acquired by Thermo Fischer Scientific), LDI (acquired by Diplomat Pharmacy), Limeade (ASX: LME), Maestro Health (acquired by AXA Group) and One Medical Group (NASDAQ:ONEM). Other prior investments include American Esoteric Laboratories (acquired by Sonic Healthcare Limited), Argus Information & Advisory Services (acquired by Verisk Analytics), Benefitfocus (NASDAQ: BNFT), CareMedic Systems (acquired by Ingenix), CLARiENT (acquired by GE Healthcare), Health Dialog (acquired by British United Provident Association), iHealth Technologies (merged with Connolly), NetSpend Corporation (acquired by TSYS), PayFlex Systems (acquired by Aetna), PharMEDium Healthcare (acquired by CD&R) and United BioSource(acquired by Medco Health Solutions).

Andrew joined Oak Investment Partners in 2003 and prior to that was a Senior Associate with Capital Resource Partners, a mezzanine capital firm where he focused on investments in healthcare and business services companies. Andrew was also a Financial Analyst in the media and communications group of Deutsche Banc Alex. Brown.

Andrew received a Bachelor of Arts degree from Princeton University.